Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St set to climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Strategy stock jumps 7% as firm shifts to active capital management
- Triller to acquire SpaceX exposure as treasury asset via fund structure
Horizon Pharma (HZNP) PT Raised to $21 at Jefferies; Reiterates Buy
November 7, 2017 8:34 AM ESTJefferies raised its price target on Horizon Pharma (NASDAQ: HZNP) to $21.00 (from $16.00) while maintaining a Buy rating following the company's 3Q earnings report.
Including the upside from the Q3 results and expected shift in operating expenses from Q3 to Q4, Jefferies raised... More
